Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
|Videos|June 12, 2021
Integrating Pharmacists in Care Teams is Critical For Patient Safety
As the drug experts, Brian Wortz, PharmD, said pharmacists may be able to recognize adverse effects before other health care professionals, ensuring patient safety and optimizing their care.
Advertisement
In a recent interview with Pharmacy Times, research pharmacist Brian Wortz, PharmD, of Cancer Treatment Centers of America, said pharmacists have a unique role to play within care teams. As the drug experts, Wortz said pharmacists may be able to recognize adverse effects before other health care professionals, ensuring patient safety and optimizing their care.
Advertisement
Related to this article
As kratom questions increase, many pharmacists and other health care professionals may remain unfamiliar it and the potential risks.
Matthew Porteus, MD, PhD, highlighted preclinical advances in automated stem cell gene editing that could improve manufacturing scalability while supporting the development of next-generation genetic medicines.
Payer requirements, prescriber habits, and operational realities ultimately determine which ICI patients receive.
Accelerated approval for patients who progressed on platinum and immunotherapy brings a new mechanism—and a familiar toxicity profile.
If approved, the combination would be the first chemotherapy-free, Bruton tyrosine kinase inhibitor–based regimen for adults with newly diagnosed mantle cell lymphoma (MCL).
Manufacturing delays, financial barriers, and complex care coordination can limit access to gene therapy, emphasizing the need for patient-centered programs and long-term follow-up.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Understanding Kratom: Pharmacology, Safety, and Regulation
2
Orforglipron Lowers Systolic BP in ATTAIN-1, ATTAIN-2 Analyses
3
How Stanford Pharmacists Help Close Heart Failure Therapy Gaps
4
GLP-1s and Obesity Care: Cardiorenal Outcomes, Prescribing Considerations, and Access Barriers
5